Oncolytic virotherapy for human malignant mesothelioma: recent advances

References

• RussellSJPengKWBellJCOncolytic virotherapyNat Biotechnol201230765867022781695
   PubMed Web of Science ®Google Scholar
• GalanisEAthertonPJMaurerMJOncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancerCancer Res2015751223025398436
   PubMed Web of Science ®Google Scholar
• GalanisEHartmannLCClibyWAPhase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancerCancer Res201070387588220103634
   PubMed Web of Science ®Google Scholar
• PorpodisKZarogoulidisPBoutsikouEMalignant pleural mesothelioma: current and future perspectivesJ Thorac Dis20135Suppl 4S397S40624102013
   PubMed Web of Science ®Google Scholar
• RoeODStellaGMMalignant pleural mesothelioma: history, controversy and future of a manmade epidemicEur Respir Rev20152413511513125726562
   PubMed Web of Science ®Google Scholar
• HusainANColbyTOrdonezNInternational Mesothelioma Interest GroupGuidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest GroupArch Pathol Lab Med2013137564766722929121
   PubMed Web of Science ®Google Scholar
• ScherpereelAAstoulPBaasPGuidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesotheliomaEur Respir J201035347949519717482
   PubMed Web of Science ®Google Scholar
• SenzerNNKaufmanHLAmatrudaTPhase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol200927345763577119884534
   PubMed Web of Science ®Google Scholar
• KucharczukJCRandazzoBChangMYUse of a “replication-restricted” herpes virus to treat experimental human malignant mesotheliomaCancer Res19975734664719012475
   PubMed Web of Science ®Google Scholar
• AdusumilliPSChanMKChunYSCisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesotheliomaCancer Biol Ther200651485316294031
   PubMed Web of Science ®Google Scholar
• AdusumilliPSChanMKHezelMRadiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesotheliomaAnn Surg Oncol200714125826917080237
   PubMed Web of Science ®Google Scholar
• AdusumilliPSEisenbergDPStilesBMIntraoperative localization of lymph node metastases with a replication-competent herpes simplex virusJ Thorac Cardiovasc Surg200613251179118817059941
   PubMed Web of Science ®Google Scholar
• AdusumilliPSStilesBMChanMKImaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex virusesJ Gene Med20068560361516475242
   PubMed Web of Science ®Google Scholar
• AdusumilliPSEisenbergDPChunYSVirally directed fluorescent imaging improves diagnostic sensitivity in the detection of minimal residual disease after potentially curative cytoreductive surgeryJ Gastrointest Surg20059811381146 discussion 1146–113716269385
   PubMed Web of Science ®Google Scholar
• HeoJReidTRuoLRandomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNat Med201319332933623396206
   PubMed Web of Science ®Google Scholar
• BreitbachCJBurkeJJonkerDIntravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humansNature201147773629910221886163
   PubMed Web of Science ®Google Scholar
• BelinLJAdyJWLewisCAn oncolytic vaccinia virus expressing the human sodium iodine symporter prolongs survival and facilitates SPECT/CT imaging in an orthotopic model of malignant pleural mesotheliomaSurgery2013154348649523890748
   PubMed Web of Science ®Google Scholar
• BraderPKellyKJChenNImaging a genetically engineered oncolytic vaccinia virus (GLV-1h99) using a human norepinephrine transporter reporter geneClin Cancer Res200915113791380119470726
   PubMed Web of Science ®Google Scholar
• KellyKJWooYBraderPNovel oncolytic agent GLV-1h68 is effective against malignant pleural mesotheliomaHum Gene Ther200819877478218754710
   PubMed Web of Science ®Google Scholar
• AcunaSAOttolino-PerryKCakoBTangNAngaritaFAMcCartJAOncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesotheliomaAnn Surg Oncol20142172259226624719018
   PubMed Web of Science ®Google Scholar
• MukherjeeSHaenelTHimbeckRReplication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generationCancer Gene Ther20007566367010830713
   PubMed Web of Science ®Google Scholar
• GarberKChina approves world’s first oncolytic virus therapy for cancer treatmentJ Natl Cancer Inst200698529830016507823
   PubMedGoogle Scholar
• ZhuZBMakhijaSKLuBTargeting mesothelioma using an infectivity enhanced survivin-conditionally replicative adenovirusesJ Thorac Oncol20061770171117409940
   PubMed Web of Science ®Google Scholar
• FukazawaTMatsuokaJNaomotoYMaedaYDurbinMLTanakaNMalignant pleural mesothelioma-targeted CREBBP/EP300 inhibitory protein 1 promoter system for gene therapy and virotherapyCancer Res200868177120712918757427
   PubMed Web of Science ®Google Scholar
• WatanabeYKojimaTKagawaSA novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapyOncogene20102981145115419935710
   PubMed Web of Science ®Google Scholar
• GotohAKannoTNagayaHGene therapy using adenovirus against malignant mesotheliomaAnticancer Res20123293743374722993314
   PubMed Web of Science ®Google Scholar
• KuboSKawasakiYYamaokaNComplete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirusJ Gene Med201012868169220635326
   PubMed Web of Science ®Google Scholar
• Takagi-KimuraMYamanoTTamamotoAEnhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesotheliomaCancer Sci2013104111433143923962292
   PubMed Web of Science ®Google Scholar
• TsurutaYPereboevaLBreidenbachMA fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancerClin Cancer Res200814113582358818519792
   PubMed Web of Science ®Google Scholar
• YamanakaMTadaYKawamuraKE1B-55 kDa-defective adenoviruses activate p53 in mesothelioma and enhance cytotoxicity of anticancer agentsJ Thorac Oncol20127121850185723154556
   PubMed Web of Science ®Google Scholar
• LiQKawamuraKYamanakaMUpregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexedCancer Gene Ther201219321822822223137
   PubMed Web of Science ®Google Scholar
• FrizelleSPGrimJZhouJRe-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regressionOncogene19981624308730959671387
   PubMed Web of Science ®Google Scholar
• YangCTYouLYehCCAdenovirus-mediated p14(ARF) gene transfer in human mesothelioma cellsJ Natl Cancer Inst200092863664110772681
   PubMedGoogle Scholar
• StermanDHHaasAMoonEA trial of intrapleural adenoviral-mediated Interferon-alpha2b gene transfer for malignant pleural mesotheliomaAm J Respir Crit Care Med2011184121395139921642245
   PubMed Web of Science ®Google Scholar
• StermanDHRecioACarrollRGA phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responsesClin Cancer Res20071315 pt 14456446617671130
   PubMed Web of Science ®Google Scholar
• StermanDHRecioAHaasARA phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusionsMol Ther201018485286020068553
   PubMed Web of Science ®Google Scholar
• TagawaMTadaYShimadaHHiroshimaKGene therapy for malignant mesothelioma: current prospects and challengesCancer Gene Ther201320315015623392201
   PubMed Web of Science ®Google Scholar
• WillmonCLSalouraVFridlenderZGExpression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesotheliomaCancer Res200969197713772019773437
   PubMed Web of Science ®Google Scholar
• SalouraVWangLCFridlenderZGEvaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacyHum Gene Ther2010211516419715403
   PubMed Web of Science ®Google Scholar
• GauvritABrandlerSSapede-PerozCBoisgeraultNTangyFGregoireMMeasles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 responseCancer Res200868124882489218559536
   PubMed Web of Science ®Google Scholar
• LiHPengKWDingliDKratzkeRARussellSJOncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapyCancer Gene Ther201017855055820379224
   PubMed Web of Science ®Google Scholar
• PhuongLKAllenCPengKWUse of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiformeCancer Res200363102462246912750267
   PubMed Web of Science ®Google Scholar
• MyersRMGreinerSMHarveyMEPreclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideClin Pharmacol Ther200782670071017971816
   PubMed Web of Science ®Google Scholar
• LappSPfankucheVMBaumgartnerWPuffCViral oncolysis – can insights from measles be transferred to canine distemper virus?Viruses2014662340237524921409
   PubMed Web of Science ®Google Scholar
• MorodomiYYanoTKinohHBioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expressionMol Ther201220476977722314292
   PubMed Web of Science ®Google Scholar
• SilberhumerGRBraderPWongJGenetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesotheliomaMol Cancer Ther20109102761276920858727
   PubMed Web of Science ®Google Scholar
• GalanisEMarkovicSNSumanVJPhase II trial of intravenous administration of Reolysin((R)) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanomaMol Ther201220101998200322871663
   PubMed Web of Science ®Google Scholar
• CominsCSpicerJProtheroeAREO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancerClin Cancer Res201016225564557220926400
   PubMed Web of Science ®Google Scholar
• KawasakiYTamamotoATakagi-KimuraMReplication-competent retrovirus vector-mediated prodrug activator gene therapy in experimental models of human malignant mesotheliomaCancer Gene Ther201118857157821660062
   PubMed Web of Science ®Google Scholar
• KuboSTakagi-KimuraMLoggCRKasaharaNHighly efficient tumor transduction and antitumor efficacy in experimental human malignant mesothelioma using replicating gibbon ape leukemia virusCancer Gene Ther2013201267167724201868
   PubMed Web of Science ®Google Scholar
• BreitbachCJArulanandamRDe SilvaNOncolytic vaccinia virus disrupts tumor-associated vasculature in humansCancer Res20137341265127523393196
   PubMed Web of Science ®Google Scholar
• BreitbachCJDe SilvaNSFallsTJTargeting tumor vasculature with an oncolytic virusMol Ther201119588689421364541
   PubMed Web of Science ®Google Scholar
• ElsedawyNBRussellSJOncolytic vaccinesExpert Rev Vaccines201312101155117224124877
   PubMed Web of Science ®Google Scholar
• CerulloVPesonenSDiaconuIOncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patientsCancer Res201070114297430920484030
   PubMed Web of Science ®Google Scholar
• StermanDHRecioAVachaniALong-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapyClin Cancer Res200511207444745316243818
   PubMed Web of Science ®Google Scholar
• GajewskiTFCorralesLNew perspectives on type I IFNs in cancerCytokine Growth Factor Rev201526217517825630967
   PubMed Web of Science ®Google Scholar
• WillmonCDiazRMWongthidaPVesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideMol Ther201119114014920978474
   PubMed Web of Science ®Google Scholar
• InoueHTaniKMultimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatmentsCell Death Differ2014211394923832118
   PubMed Web of Science ®Google Scholar
• AchardCBoisgeraultNDelaunayTTangyFGregoireMFonteneauJFInduction of immunogenic tumor cell death by attenuated oncolytic measles virusJ Clin Cell Immunol201561291
   Google Scholar
• GuillermeJBBoisgeraultNRouloisDMeasles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cellsClin Cancer Res20131951147115823339127
   PubMed Web of Science ®Google Scholar
• FonteneauJFGuillermeJBTangyFGregoireMAttenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cellsOncoimmunology201325e2421223762802
   PubMed Web of Science ®Google Scholar
• TelJde VriesIJPotential applications for plasmacytoid dendritic cells in cancer immunotherapyImmunotherapy201241097998223148748
   PubMed Web of Science ®Google Scholar
• RussellSJFederspielMJPengKWRemission of disseminated cancer after systemic oncolytic virotherapyMayo Clinic Proceed2014897926933
   PubMed Web of Science ®Google Scholar
• EngelandCEGrossardtCVeinaldeRCTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapyMol Ther201422111949195925156126
   PubMed Web of Science ®Google Scholar
• RankiTJoensuuTJägerELocal treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8 T-cell response, prominent infiltration of CD8 lymphocytes and Th1 type polarizationOncoimmunology2014310e95893725941579
   PubMed Web of Science ®Google Scholar
• RajaniKAlonso-CaminoVBoisgeraultNVileRViral platforms for expression of tumor antigens in cancer immunotherapyReesRCTumor Immunology and ImmunotherapyOxfordOxford University Press2014217234
   Google Scholar
• GuillotFBoutinBBlanquartCVaccination with epigenetically treated mesothelioma cells induces immunisation and blocks tumour growthVaccine201129335534554321619908
   PubMed Web of Science ®Google Scholar
• LeclercqSGueugnonFBoutinBA 5-aza-2′-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesotheliomaEur Respir J20113851105111621540307
   PubMed Web of Science ®Google Scholar
• NguyênTLAbdelbaryHArguelloMChemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysisProc Natl Acad Sci U S A200810539149811498618815361
   PubMed Web of Science ®Google Scholar
• OtsukiAPatelAKasaiKHistone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic virusesMol Ther20081691546155518648350
   PubMed Web of Science ®Google Scholar
• NguyenTLWilsonMGHiscottJOncolytic viruses and histone deacetylase inhibitors – a multi-pronged strategy to target tumor cellsCytokine Growth Factor Rev2010212–315315920395162
   PubMed Web of Science ®Google Scholar
• ForbesNEAbdelbaryHLupienMBellJCDialloJSExploiting tumor epigenetics to improve oncolytic virotherapyFront Genet2013418424062768
   PubMedGoogle Scholar